Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics

Michael Paulzen, Georgios Schoretsanitis*, Benedikt Stegmann, Christoph Hiemke, Gerhard Gruender, Koen R. J. Schruers, Sebastian Walther, Sarah E. Lammertz, Ekkehard Haen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalProgress in Neuro-Psychopharmacology & Biological Psychiatry
Volume76
DOIs
Publication statusPublished - 2 Jun 2017

Keywords

  • Antipsychotics
  • Risperidone
  • Psychopharmacology
  • Pharmacokinetics
  • Therapeutic drug monitoring
  • CYTOCHROME-P450 2D6
  • LEVOMEPROMAZINE
  • SCHIZOPHRENIA
  • MELPERONE
  • METABOLISM
  • CYP2D6
  • 9-HYDROXYRISPERIDONE
  • HALOPERIDOL
  • QUETIAPINE
  • INHIBITOR

Cite this